AIM ImmunoTech Inc. (NYSE:AIM) Director Stewart Appelrouth Purchases 81,953 Shares

AIM ImmunoTech Inc. (NYSE:AIM) Director Stewart Appelrouth bought 81,953 shares of the firm’s stock in a transaction that occurred on Wednesday, November 20th. The shares were acquired at an average cost of $0.19 per share, for a total transaction of $15,571.07. Following the purchase, the director now directly owns 321,752 shares in the company, valued at $61,132.88. This trade represents a 34.18 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

AIM ImmunoTech Stock Up 1.0 %

Shares of AIM ImmunoTech stock traded up $0.00 on Friday, reaching $0.21. The stock had a trading volume of 140,194 shares, compared to its average volume of 291,699. The company has a 50 day moving average price of $0.26 and a 200 day moving average price of $0.33. The stock has a market capitalization of $13.63 million, a P/E ratio of -0.45 and a beta of -0.36. The company has a quick ratio of 0.75, a current ratio of 0.75 and a debt-to-equity ratio of 0.05. AIM ImmunoTech Inc. has a 1 year low of $0.16 and a 1 year high of $0.62.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on AIM. Ascendiant Capital Markets decreased their target price on shares of AIM ImmunoTech from $5.25 to $5.00 and set a “buy” rating on the stock in a research report on Tuesday, September 3rd. Maxim Group cut their price objective on AIM ImmunoTech from $2.00 to $1.00 and set a “buy” rating on the stock in a research report on Tuesday, October 22nd.

Institutional Trading of AIM ImmunoTech

A hedge fund recently bought a new stake in AIM ImmunoTech stock. Armistice Capital LLC bought a new stake in AIM ImmunoTech Inc. (NYSE:AIM) in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 4,078,000 shares of the company’s stock, valued at approximately $1,520,000. Armistice Capital LLC owned about 7.92% of AIM ImmunoTech as of its most recent SEC filing. Institutional investors own 12.02% of the company’s stock.

AIM ImmunoTech Company Profile

AIM ImmunoTech Inc, an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS).